OTTAWA, Nov. 28, 2017 /CNW/ - In response to the launch of the Ontario Progressive Conservative Party election platform, Innovative Medicines Canada welcomes the policy commitments aimed at improving access to innovative medicines for patients in Ontario.
Innovative Medicines Canada member companies are bringing new and important treatments to Canada. By increasing support for rare disease drugs, funding take-home oral cancer drugs and allowing patients on ground breaking clinical trials to move to public funding post trial, the Ontario PC platform would make access to new treatments possible.
"Innovative medicines play a critical role in patients' health. Ontario's patients would benefit from these commitments that both improve access to new drugs and support Ontario's robust clinical trials eco-system" said Pamela Fralick, President of Innovative Medicines Canada.
With an election in Ontario just over six months away Innovative Medicines Canada is eager to work with all political parties in developing programs that will have the best standard of care, and support a healthcare system that achieves the best outcomes for patients by providing access to a full range of medicines to meet diverse patient needs.
Innovative Medicines Canada is committed to further improve access to medicines for Ontarians, engage with governments on finding solutions to Canada's vulnerable populations, as well as provide predictability for the government and manufacturers.
SOURCE Innovative Medicines Canada
For further information: Sarah Dion-Marquis, Director, Media and Public Relations, 613-769-6510, firstname.lastname@example.org
ABOUT INNOVATIVE MEDICINES CANADA Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare...